Creative Bio-Peptides Competitors and Similar CompaniesClear all

Creative Bio-Peptides's competitors and similar companies include Kinnov Therapeutics, Upstream Bio, Albert Labs and AbClon.

	Creative Bio-Peptides Creative Bio-Peptides (CBP) is a company that develops disease-modifying oral chemokine antagonist peptides that repair and regenerate damaged neurons.	Kinnov Therapeutics Kinnov Therapeutics is a company dedicated to the research and development of therapies against addiction.	Upstream Bio Upstream Bio is a clinical-stage biotechnology company that develops treatments for inflammatory diseases.	Albert Labs Albert Labs is a clinical research and drug development company.	AbClon AbClon (앱클론(주)) is a developer, manufacturer, and distributor of antibody drugs.
Founding Date	Founding Date 2017	Founding Date N/A	Founding Date 2021	Founding Date 2009	Founding Date 2010
Type	Type Private	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy	Tags Healthcare clinical research drug development therapy
Locations	Locations Rockville, US HQ	Locations Orléans, FR HQ	Locations Waltham, US HQ	Locations Burnaby, CA HQ Porto, PT Manchester, GB	Locations KR HQ
Employees	Employees 4	Employees N/A	Employees 38	Employees N/A	Employees N/A
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 1.3 b	Valuation ($) 401.7 k	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $2.9m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₩2.3b (FY, 2024)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $23m (FY, 2025)	Cost of goods N/A	Cost of goods (₩74.1m) (FY, 2024)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit ($20.2m) (FY, 2025)	Gross profit N/A	Gross profit ₩2.4b (FY, 2024)
Net income	Net income N/A	Net income N/A	Net income ($143.4m) (FY, 2025)	Net income ($7.1m) (FY, 2022)	Net income (₩16.3b) (FY, 2024)